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PURPOSE. Keratoconus is a progressive disorder of the cornea
that can lead to severe visual impairment or blindness. Al-
though several genomic regions have been linked to rare fa-
milial forms of keratoconus, no genes have yet been defini-
tively identified for common forms of the disease.
METHODS. Two genome-wide association scans were under-
taken in parallel. The first used pooled DNA from an Australian
cohort, followed by typing of top-ranked single-nucleotide
polymorphisms (SNPs) in individual DNA samples. The second
was conducted in individually genotyped patients, and con-
trols from the USA. Tag SNPs around the hepatocyte growth
factor (HGF) gene were typed in three additional replication
cohorts. Serum levels of HGF protein in normal individuals
were assessed with ELISA and correlated with genotype.
RESULTS. The only SNP observed to be associated in both the
pooled discovery and primary replication cohort was rs1014091,
located upstream of the HGF gene. The nearby SNP rs3735520
was found to be associated in the individually typed discovery
cohort (P  6.1 107). Genotyping of tag SNPs around HGF
revealed association at rs3735520 and rs17501108/rs1014091 in
four of the five cohorts. Meta-analysis of all five datasets together
yielded suggestive P values for rs3735520 (P  9.9 107) and
rs17501108 (P  9.9 105). In addition, SNP rs3735520 was
found to be associatedwith serumHGF level in normal individuals
(P  0.036).
CONCLUSIONS. Taken together, these results implicate genetic vari-
ation at the HGF locus with keratoconus susceptibility. (Invest
Ophthalmol Vis Sci. 2011;52:8514–8519) DOI:10.1167/iovs.11-
8261
Keratoconus is a corneal disorder with an incidence of ap-proximately 1 in 2000 and a prevalence of 54.5 per
100,000.1 The disorder leads to severe refractive error and irreg-
ular astigmatism. It is typically bilateral and is characterized by
progressive thinning of the cornea, leading to asymmetric bulging
and, in advanced cases, formation of a conical cornea.1
Based on the results of twin studies, reports of familial aggre-
gation, and formal segregation analysis (reviewed in Ref. 2), ker-
atoconus appears to have a strong genetic component; however,
to date, few if any genes have been reliably identified. Approxi-
mately 6% to 23% of individuals with keratoconus report a posi-
tive family history.2 Linkage to multiple loci has been reported
through a combination of linkage studies in extended pedigrees
(3p14-q133; 5q14-q214; 15q22-q245; 1p36 and 8q246; and
13q327), in collections of small families and sibling pairs (2p248;
16q22-q239; 9q34, 5q32-q33, and 5q21.210; and 14q11.211), and
in an identity-by-descent approach (20q12).12 Although the caus-
atives genes in these regions remain to be elucidated, several reports
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have been made of candidate genes associated with keratoconus.
The best studied of these is VSX1, the visual system homeobox-1
gene, with mutations identified in a small number of keratoconus
patients,13–17 although not all studies support these findings.18–21 A
7-bp deletion in intron 2 of the SOD1 gene was described in two
families,22 but no mutations were reported in another study.23
Promoter variants in IL1B were also nominally associated with
keratoconus in a small Korean cohort.24 Several coding polymor-
phisms in the COL4A3 and COL4A4 genes encoding the structural
proteins collagens were also found to be associated with kerato-
conus.25 These results are awaiting further replication.
In addition to the candidate gene approach, recent develop-
ments in genotyping technology have made feasible large-scale
genetic studies with hundreds of thousands of dense markers,
such as genome-wide association studies (GWASs). Understand-
ing of genetic susceptibility to ophthalmic diseases, such as glau-
coma, macular degeneration, and refractive error,26–28 and ocular
quantitative traits, such as corneal thickness,29–31 has been
greatly enhanced by recent GWASs.
We present the results of two genome-wide association stud-
ies, both of which point to the HGF (hepatocyte growth factor)
gene as a keratoconus susceptibility locus. Two SNPs located
upstream of the HGF gene on chromosome 7 showed repeated
association with keratoconus in independent cohorts of patients,
thus providing initial evidence that they may be associated with
the common form of keratoconus in Caucasian patients. We also
present data indicating association of the same SNPs with the
serum HGF level in normal participants.
MATERIALS AND METHODS
Multiple patient cohorts were recruited and examined as described
below. All studies adhered to the tenets of the Declaration of Helsinki
and were approved by the relevant institutions; all participants gave
written informed consent. All participants (cases and controls) were
Caucasian. A flow chart indicating the cohorts studied and the geno-
typing strategies is given in Supplementary Figure S1 (http://www.
iovs.org/lookup/suppl/doi:10.1167/iovs.11-8261/-/DCSupplemental).
Definition of Keratoconus
The diagnosis of keratoconus was performed by an ophthalmologist based
on clinical examination and videokeratography pattern analysis. Clinical
examination included slit lamp biomicroscopy, cycloplegic retinoscopy,
and fundus evaluations. Slit lamp biomicroscopy was used to identify
stromal corneal thinning, Vogt’s striae, or a Fleischer ring. A retinoscopic
examination was performed with a fully dilated pupil to determine the
presence or absence of retroillumination signs of keratoconus, such as the
oil droplet sign and scissoring of the red reflex. Videokeratography eval-
uation was performed on each eye by topographic modeling (Topo-
graphic Modeling System; Computed Anatomy, New York, NY) or with
corneal topographers (ARK-9000; Nidek Inc. Freemont, CA, or Orbscan;
Bausch & Lomb, Madison, NJ). Patients were considered as having kera-
toconus if they had at least one clinical sign of the disease and by
confirmatory videokeratography map with an asymmetric bowtie pattern
with skewed radial axis above and below the horizontal meridian (AB/
SRAX).32 A history of penetrating keratoplasty performed because of
keratoconus was also sufficient for inclusion as a case in the Australian and
Northern Ireland cohorts.
Australian GWAS
Discovery Cohort. The protocol was approved by the Southern
Adelaide Health Service/Flinders University Human Research Ethics Com-
mittee. Participants with keratoconus (n 97) were ascertained through
the eye clinic of Flinders Medical Centre. Unaffected controls (n  216)
were recruited from assisted living facilities (nursing homes) in Adelaide
and from healthy volunteers. All controls had an ocular examination and
medical history taken.
Replication Cohorts. Rep1. An additional 39 cases and 72
controls from Flinders Medical Centre were recruited, along with 57
patients recruited from the Ophthalmology Department of the Belfast
Health and Social Care National Health System Trust. The study was
approved by the Northern Ireland Research Ethics Committee.
Rep2. This cohort was recruited through an Australia-wide mailing
to members of Keratoconus Australia, a community-based support group
for patients. Clinical data were obtained from the participants’ eye care
practitioner, and patients were included in the study only if they met the
recruitment criteria—in total, 186 cases. An additional more recently
recruited 29 cases from Northern Ireland were also included in this
cohort. Genotype data for the SNPs of interest were downloaded for
112 unrelated CEU samples (CEPH:Utah residents with ancestry
from northern and western Europe) from the International HapMap
Project (www.hapmap.org) to be used as controls.
Genotyping and Analysis. Genomic DNA was extracted from
peripheral whole blood with a kit (QIAamp Blood Maxi Kit; Qiagen,
Valencia, CA), for each Australian participant, and with another kit (Pure-
gene; Gentra Systems, Minneapolis, MN), for Northern Ireland partici-
pants, according to the manufacturers’ protocols. Equimolar DNA pools
were generated in triplicate for discovery cases (n  97) and controls
(n  216) after step-wise dilution to 75 ng/L and accurate quantitation
of all samples at each dilution stage in a dsDNA quantitation assay (Pi-
coGreeen; Invitrogen, Carlsbad, CA) performed on a plate reader (Fluo-
roskan; Thermo Fisher Scientific, Waltham, MA). A total of 451 ng of DNA
from each sample was added to the pool.
Genome-wide genotyping was conducted by hybridization to SNP
arrays (HumanHap 1M; Illumina, San Diego, CA). The case pool was
hybridized to two independent arrays, and the larger control pool to four
arrays. The output of the raw red and green bead scores from the
genotyping stage was available for the pooled data analysis. The data
processing protocol was similar to a method described previously.33
Before the raw scores were calculated, SNPs with more than 10% negative
scores on each array were excluded, as well as the SNPs with the sum of
mean red and green scores lower than 1200 across each array. This step
was included to ensure that the calibration was performed on a pre-
cleaned dataset. A normalization/correction factor (corr) was calculated
by forcing the mean value of the pooling allele frequency to be 0.5 over
all SNPs on each stripe (the Human 1M-Duo V3 array has six stripes on a
single array). The pooling allele frequency (PAF) was then estimated based
on the raw red intensities and the corrected green intensities for all the
SNPs [PAF  red/(red  green/corr)].
A final set of autosomal SNPs meeting the criteria (1) more than 20
probes in each pool; (2) an MAF in the HapMap CEU samples greater
than 5%; (3) no large differences (0.3) between PAF and HapMap
CEU allele frequency; and (4) estimated k value between 0.333 and 3
(where k is the estimated coefficient of unequal amplification of
alleles), without a significant variance difference between case and
control pools (i.e., the log10 transformed P values from an F test on the
ratio of case control pool variances were smaller than 6), was taken
forward to a linear regression model.34 The underlying idea was to
regress the pooling allele frequency on the case–control status for each
SNP and estimate the pooling error across all the SNPs (for more
details, see MacGregor et al.34,35). The P value from comparing the test
statistic in the paper by MacGregor et al. (T2  x) to a 2 distribution
with 1° of freedom was computed to assess the significance of allele
frequency difference between the two pools.
Highly ranked SNPs from the pooled GWAS of Australian samples
were prioritized for genotyping in individual DNA samples and further
follow-up according to the following criteria: (1) SNP reaching a signifi-
cance threshold of P 1 107 or better; (2) SNP present in a cluster of
at least two SNPs within 100 kb of each other, with P 1 104; or (3)
SNP highly ranked with P  1 105 and intragenic in a biologically
relevant candidate gene. Additional SNPs representing the next best
ranked SNP in any of the regions pinpointed through the above criteria
were also entered into the assay design process to best use the multi-
plexes. In addition, to be included in follow-up individual typing, the SNP
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must be suitable for genotyping (Sequenom, San Diego, CA) and able to
multiplex with other chosen SNPs. In total, 52 SNPs were genotyped in
three multiplexes (iPlex Gold chemistry; Sequenom) and allelic detection
by mass spectrometry (MassArray; Sequenom) at the Australian Genome
Research Facility (Brisbane, Australia) and were considered to be validated
if they reached a nominal P  9.0 103 or better. This validation
threshold was chosen to allow a manageable number of candidate genes
for further analysis. Additional tag SNPs around the HGF gene as reported
by Yanovitch et al.36 were also typed in both the discovery and Rep1
replication samples in individual DNA samples. The associated HGF SNPs
rs17501108 and rs3735520 were typed in the Rep2 replication cohort by
using predesigned genotyping probes (TaqMan; Applied Biosystems, Inc.
[ABI], Foster City, CA) on a real-time PCR instrument (StepOne Plus; ABI).
Association analysis was undertaken in PLINK.37
U.S. GWAS
Discovery Cohort: US1. This discovery cohort consisted of
222 clinically affected Caucasian keratoconus cases enrolled in a GWAS
as a part of the longitudinal videokeratography and genetic study at the
Cornea Genetic Eye Institute (Los Angeles, CA).38 Caucasian controls
(n 3324) were obtained from the Cardiovascular Health Study (CHS),
a population-based cohort study of risk factors for cardiovascular dis-
ease and stroke in adults 65 years of age or older, recruited at four field
centers. Predominantly Caucasian individuals (n  5201) were re-
cruited in 1989 to 1990 from random samples of Medicare eligibility
lists, followed by an additional 687 African-Americans recruited in
1992 to 1993 (total, n 5888). The CHS was approved by the institu-
tional review board at each recruitment site, and subjects provided
informed consent for the use of their genetic information. African-
American CHS participants were excluded from analysis due to an
insufficient number of ethnically matched cases.39,40
Replication Cohort: US2. An independent group of 304 ker-
atoconus cases and 518 normal controls were recruited as a part of the
collaborative effort to form a replication cohort. Three independent
groups of clinically affected keratoconus patients were recruited at
three major sites: The Cornea Genetic Eye Institute (n  232; Cedars-
Sinai Medical Center, Los Angeles, CA); The Jules Stein Eye Institute
(n  26; UCLA, Los Angeles, CA); and the University Hospitals Eye
Institute (n  46; Case Western Reserve University, Cleveland, OH).
Normal controls were recruited at the Cornea Genetic Eye Institute.
Institutional Review Board approval was obtained at all clinic sites.
Genotyping and Analysis. DNA was extracted from EBV-
transformed lymphoblastoid cell lines established from peripheral
whole blood of each study participant (NucleoSpin Tissue kit; Mach-
erey-Nagel, Inc., Bethlehem, PA). A salt-extraction protocol was used
to obtain DNA from buffy coats.41
Genotyping in the discovery cohort (US1) was performed at Medical
Genetics Institute at Cedars Sinai Medical Center using a whole genome
genotyping bead chip assay (Human CNV370 Quad; Illumina), according
to the manufacturer’s protocol.42,43 The average genotyping rate for
samples passing quality control was 99.77%. Approximately 320,000 SNPs
were used for the analysis after SNPs with minor allele frequency of less
than 0.05 and/or a call rate of less than 0.9 were excluded.
Genotyping in the replication cohort (US2) was performed with a
custom bead chip assay (iSelect Infinium; Illumina).44 Tagging and proxy
SNPs were selected in a 100-kb genomic region at 7q21.1, overlapping the
HGF gene. General criteria were an r2 threshold of 0.8 and an MAF of 0.05
in the CEU panel, using the software Tagger as implemented in Haplo-
view45,46 and data from the CEPH population in the International HapMap
project, release 2.47,48 In total, a panel of 4905 SNPs was designed that
were compatible with the bead chip technology, of which 4650 SNPs
remained after clustering quality control, including the SNPs reported
here. The average genotyping rate for samples genotyped on this platform
and passing quality control was 99.98%. Genotyping concordance among
20 replicated samples was 100%.
Meta-analysis
Meta-analysis of all cohorts was conducted by using Fisher’s combined-
probability test. The test was applied when all cohorts showed asso-
ciation in the same direction, as this test combines P values from
multiple studies. Calculations were conducted manually (Excel; Mi-
crosoft, Redmond, WA).
Measurement of Serum HGF Concentration
Serum was obtained from whole blood collected from 191 normal
control participants (controls from the pooled GWAS discovery co-
hort). Aliquots of serum were stored frozen at 80°C and thawed
immediately before analysis. Serum HGF concentration was measured
with a human HGF ELISA kit (RayBiotech, Inc., Norcross GA), per the
manufacturer’s protocol. Each sample was analyzed in duplicate in two
independent experiments. A coefficient of variation of 12% was
required for inclusion in the analysis, and outliers (values 2000; n 
4) were removed. A total of 78 participants were included in the
analysis (SPSS Statistics, ver. 17.0; SPSS, Chicago, IL). Nonparametric
Kruskal-Wallis and Mann-Whitney U tests were used to assess the
differences in serum HGF concentration between genotypes of SNPs
rs3735520 and rs17501108.
RESULTS
Demographics for each cohort are given in Table 1. In all
cohorts, controls were significantly older than cases, to reduce
misclassification error. There were also differences in the ratio
of males to females; however, the direction of this bias was not
consistent between cohorts (Table 1).
A genome-wide association scan of pooled DNA from Aus-
tralian cases was conducted to identify candidate genes for
further analysis in keratoconus. Quality-control measures were
used in obtaining allele frequency estimates from the pooled
DNA for 745,982 SNPs. In total, four SNPs reached genome-wide
significance of P  5  108 with an additional four SNPs
TABLE 1. Demographics of the Study Cohorts
n
Mean
Age (SD) % Female
Case Control Case Control P Case Control P
Discovery (pooled) 97 216 48.4 (15.5) 76.7 (8.5) 0.001 53.0 28.9 0.002
Rep1 96 72 42.7 (15.1) 72.9 (11.3) 0.001 38.5 9.9 0.001
Rep2 215 112 41.2 (14.8) 71.6 (8.5)* 0.001 39.3 50.1 0.054
Discovery (individual) US1 222 3246 43.8 (13.3) 72.3 (5.4) 0.001 43.7 39.2 0.188
US2 304 518 42.9 (15.6) 45.4 (13.7) 0.017 31.6 47.7 0.001
Total 933 4164
Comparisons were made with a t-test for age and 2 test for sex.
* Age was available only for 68/112 controls in Rep2, and this cohort was not examined.
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reaching the P  1  107 threshold (Supplementary Table S1,
http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.11-8261/-/
DCSupplemental). Fifty-two top ranked SNPs were typed in in-
dividual case and control DNA samples and 19 reached the
validation threshold (Supplementary Table S1), representing
13 independent loci. The only SNP showing any level of rep-
lication in the small Rep1 cohort was rs1014091, located up-
stream of the HGF gene.
Simultaneously with the Australian GWAS, the US1 cohort
underwent genome-wide genotyping in individual DNA sam-
ples. Suggestive association was identified with HGF SNPs
rs1014091 (P  0.018; in complete LD with rs17501108) and
rs3735520 (P  6.1  107 OR[95% CI]  1.63 [1.35–1.98]).
The latter was the fourth ranked SNP in the GWAS and, in
conjunction with the data from the Australian study, was pri-
oritized for replication.
Genetic variation in and around HGF was then investigated
further for association. Tag SNPs in the region of the HGF gene
(rs12536657, rs2286194, rs3735520, and rs17501108) were
genotyped in the Australian samples (Discovery and Rep1)
along with the SNPs from the array (rs7799610 and
rs1014091). Tag SNP rs17501108 is in complete linkage dis-
equilibrium (r2 1.0) with array SNP rs1014091 in the Cauca-
sian HapMap data, although both SNPs were typed to ensure
comparison with the literature and consistency of results be-
tween cohorts. Both these SNPs are associated with keratoco-
nus (Table 2) and survive Bonferroni correction for the six
SNPs analyzed in and around this gene (P  0.0004 for
rs1014091 and P  0.0002 for rs17501108). SNP rs3735520
was also associated (P  0.002).
The associated SNPs, rs3735520 and rs17501108 were then
typed in the Australian Rep2 and US2 replication cohorts.
Association of SNP rs17501108 was replicated in Rep2 (P 
0.006; Table 3). No significant association (P  0.05) was
observed in the US2 replication cohort; however, the odds
ratios are in the same direction with those observed in the
other cohorts. All results for these SNPs are summarized in
Table 3. Meta-analysis of HGF SNPs in all cohorts suggested that
SNP rs3735520 is associated with keratoconus with a genome-
wide suggestive P  9.9  107. A less significant P 
9.9  105 was calculated for SNP rs17501108/rs1014091.
To assess the effect of SNP rs3735520 on HGF levels, we
obtained serum HGF concentration that met quality control
standards from 78 control participants (serum was not avail-
able from the keratoconus patients). According to a nonpara-
metric Kruskal-Wallis test, there was a significant trend for
increased serum HGF concentration with each T allele of the
SNP (Table 4, P  0.036). The minor T allele is also the risk
allele for keratoconus. This association was also significant
under both dominant and recessive genetic models. A sim-
ilar relationship was found with the risk G allele of
rs17501108, although it did not reach statistical significance
(data not shown). No correlation was observed between
serum HGF concentration and age in this cohort (Pearson’s
correlation 0.082; P  0.47).
DISCUSSION
Two independent genome-wide association studies both identi-
fied positive association of keratoconus with SNPs in the pro-
moter and upstream region of the HGF gene. Positive association
was also observed in another independent cohort with a com-
bined meta-analysis P  9.9 107 in five cohorts. Although
neither study was able to pinpoint this gene directly, analysis of
the two GWASs in tandem identified HGF as a prominent candi-
date gene for further evaluation.
The odds ratios observed in this study are in the range of 1.5
to 2.2, indicating a relatively large effect size for a common
complex disease. However, there is a possibility that they are over
TABLE 2. Association Results for Tag SNPs in the HGF Gene in the Pooled and Rep1
Samples Combined
SNP
Alleles
Maj/Min
MAF Controls
(n  287)
MAF Cases
(n  196) P OR (95% CI)
rs7799610 G/A 0.078 0.072 0.74 1.08 (0.66–1.78)
rs12536657 G/A 0.227 0.195 0.24 1.21 (0.88–1.68)
rs2286194 T/A 0.167 0.204 0.15 1.28 (0.92–1.78)
rs3735520 C/T 0.413 0.513 0.002 1.50 (1.15–1.94)
rs17501108 G/T 0.144 0.067 0.0002 2.33 (1.17–3.69)
rs1014091 G/A 0.147 0.072 0.0004 2.22 (1.41–3.48)
The minor allele and its frequencies in cases and controls are shown. The OR with 95% CI is expressed
with respect to the risk allele. Significant P values are highlighted bold.
TABLE 3. Results of Association Testing of HGF SNPs in Multiple Cohorts
Cohort
rs3735520 rs17501108/rs1014091*
MAF
P OR (95% CI)
MAF
P OR (95% CI)Controls Cases Controls Cases
PooledRep1 0.41 0.51 0.002 1.50 (1.15–1.94) 0.14 0.07 0.0002 2.33 (1.17–3.69)
Rep2 0.43 0.45 0.664 1.08 (0.76–1.51) 0.17 0.10 0.006 1.93 (1.20–3.10)
US1 0.45 0.57 6.1  107 1.63 (1.35–1.98) 0.11 0.07 0.018 1.56 (1.07–2.24)
US2 0.46 0.47 0.655 1.05 (0.86–1.28) 0.11 0.10 0.658 1.08 (0.77–1.50)
The minor allele frequency in cases and controls are shown. OR (95% CI) is also shown, expressed with respect to the risk allele defined in
the pooled samples.
* As rs17501108 and rs1014091 are in very strong LD (r2  0.95 in Australian samples), the results for rs17501108 are presented for Australian
samples and rs1014091 for U.S. samples, due to different genotyping strategies in the two cohorts.
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inflated in this study because of the “winner’s curse.”49 Impor-
tantly, all odds ratios (including those from US2 that did not reach
significance) indicate an association in the same direction, pro-
viding further confidence in the validity of the association.
The HGF gene has been reported to be associated with
refractive error in multiple populations including myopia in
Han Chinese50 and both myopia and hypermetropia in Cauca-
sians.36,51 The refractive power of the eye is determined at
least in part by the shape of the cornea, which is severely
altered in keratoconus, thus suggesting overlap between the
genetic determinants of these complex ophthalmic conditions.
HGF (OMIM 142409; Online Mendelian Inheritance in Man;
http://www.ncbi.nlm.nih.gov/Omim/, National Center for Bio-
technology Information, Bethesda, MD), also known as scatter
factor, is an inducible cytokine involved in a variety of cellular
processes.52 In general, HGF is produced and excreted by mes-
enchymal cells, such as fibroblasts. It remains bound to the ex-
tracellular matrix until it becomes activated by cleavage into its 
and  chains by plasminogen activators.52,53 It is then active on
cells expressing the c-MET receptor, which are typically epithelial
cells that do not expressHGF.53 The signals transduced via c-MET
are varied and can include proliferation, cell scattering or changes
in morphology, dependent on the context. The intracellular sig-
nals appear to be mediated through autophosphorylation of the
c-MET intracellular docking region followed by docking of phos-
phatidylinositol-3-kinase (PI3K) or growth factor receptor–bound
protein (Grb2).52,53
The HGF gene and its receptor c-MET are both known to be
expressed in the cornea by all three cellular layers, although at
lower levels in the epithelium than in the stroma and endothe-
lium.54 The protein is also produced by the lacrimal glands and is
found in tears.55 HGF expression in corneal keratinocytes is up-
regulated in response to corneal injury, although levels of the
receptor are unchanged.55 Primary cultures of epithelial and en-
dothelial cells are both responsive to the proliferative signals of
HGF, whereas stromal fibroblasts are not, despite expressing the
receptor.54 Thus, the interplay of HGF production and respon-
siveness in the cornea is complex. The observed genetic associa-
tion and evidence that the same genetic variants are associated
with elevated serum levels of the protein suggests HGF may be
directly involved in the development of keratoconus.
The inflammatory cytokines IL-6 and TNF have been de-
tected at elevated levels in tears of patients with severe keratoco-
nus56 and also in eyes with subclinical keratoconus.57 The human
and mouse HGF gene promoters both contain binding sites for
the proinflammatory cytokine IL-6 that have been shown to be
active in murine cell culture models.58 Thus, the mechanism of
HGF association with keratoconus may be through inflammatory
pathways.
The associated SNP rs3735520 is located 1.5 kb upstream of
the transcription start site of theHGF gene. It is not known at this
time whether this particular SNP is directly involved in the tran-
scription of HGF or tags other variants that may affect transcrip-
tion factor binding sites and alter the efficiency or timing of
transcription of this gene. In this study, we did detect a significant
association of this SNP with serum HGF levels in control partici-
pants. Carriers of the minor T allele (which is the at-risk allele for
keratoconus) have, on average, a higher concentration of serum
HGF than the CC homozygotes. Additional studies in a larger
cohort of controls and, more important, in patients with kerato-
conus, are needed to further our understanding of the relation-
ship between rs3735520 genotypes and serum HGF levels. In
addition, HGF levels may be more relevant in tears or the corneas
of patients than circulating serum levels. However, these data
indicate a relationship between the SNPs associated with kerato-
conus and expression of the HGF gene.
In summary, association of common variations in HGF with
keratoconus brings new insight in its pathogenesis by identifying
a signaling pathway not previously directly implicated in this
disease.
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